25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ENDV (Endonovo) Stock Analysis
Buy, Hold or Sell?

Let's analyze Endonovo together

I guess you are interested in Endonovo Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Endonovo’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Endonovo’s Price Targets

I'm going to help you getting a better view of Endonovo Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Endonovo Therapeutics Inc

I send you an email if I find something interesting about Endonovo Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Endonovo (30 sec.)










1.2. What can you expect buying and holding a share of Endonovo? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$-0.02
Expected worth in 1 year
$-0.03
How sure are you?
20.0%

+ What do you gain per year?

Total Gains per Share
$0.00
Return On Investment
-2,245.4%

For what price can you sell your share?

Current Price per Share
$0.00
Expected price per share
$0.0001 - $0.0003
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Endonovo (5 min.)




Live pricePrice per Share (EOD)
$0.00
Intrinsic Value Per Share
$-0.01 - $0.01
Total Value Per Share
$-0.03 - $-0.02

2.2. Growth of Endonovo (5 min.)




Is Endonovo growing?

Current yearPrevious yearGrowGrow %
How rich?-$27.2m-$23.5m-$2.9m-11.0%

How much money is Endonovo making?

Current yearPrevious yearGrowGrow %
Making money-$655.2k-$253.8k-$401.4k-61.3%
Net Profit Margin-10,856.3%-20,276.8%--

How much money comes from the company's main activities?

2.3. Financial Health of Endonovo (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#842 / 881

Most Revenue
#643 / 881

Most Profit
#220 / 881

Most Efficient
#833 / 881
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Endonovo?

Welcome investor! Endonovo's management wants to use your money to grow the business. In return you get a share of Endonovo.

First you should know what it really means to hold a share of Endonovo. And how you can make/lose money.

Speculation

The Price per Share of Endonovo is $0.0001. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Endonovo.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Endonovo, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.02. Based on the TTM, the Book Value Change Per Share is $0.00 per quarter. Based on the YOY, the Book Value Change Per Share is $0.00 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Endonovo.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.00-485.4%0.00-596.8%0.00-319.1%0.00-1,178.7%0.00-1,174.1%0.00-1,502.8%
Usd Book Value Change Per Share0.00-421.9%0.00-561.4%0.00-2,152.2%0.00-700.5%0.00-734.3%0.00-510.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.00-421.9%0.00-561.4%0.00-2,152.2%0.00-700.5%0.00-734.3%0.00-510.6%
Usd Price Per Share0.00-0.00-0.01-0.01-0.02-0.12-
Price to Earnings Ratio-0.10--0.27--1.21--0.80--3.59--18.88-
Price-to-Total Gains Ratio-0.47--1.13--5.49--4.50--22.68--112.01-
Price to Book Ratio-0.01--0.03--0.50--0.40--1.65--12.24-
Price-to-Total Gains Ratio-0.47--1.13--5.49--4.50--22.68--112.01-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0001
Number of shares10000000
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (10000000 shares)-5,613.55-7,343.06
Gains per Year (10000000 shares)-22,454.22-29,372.25
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-22454-224640-29372-29382
20-44908-449180-58744-58754
30-67363-673720-88117-88126
40-89817-898260-117489-117498
50-112271-1122800-146861-146870
60-134725-1347340-176233-176242
70-157180-1571880-205606-205614
80-179634-1796420-234978-234986
90-202088-2020960-264350-264358
100-224542-2245500-293722-293730

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%2.010.00.016.7%3.017.00.015.0%7.033.00.017.5%8.048.00.014.3%
Book Value Change Per Share0.04.00.00.0%1.011.00.08.3%2.018.00.010.0%8.032.00.020.0%10.046.00.017.9%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.056.00.0%
Total Gains per Share0.04.00.00.0%1.011.00.08.3%2.018.00.010.0%8.032.00.020.0%10.046.00.017.9%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Endonovo Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.000-0.001+33%-0.002+410%-0.001+66%-0.001+74%-0.001+21%
Book Value Per Share---0.025-0.024-3%-0.020-18%-0.021-14%-0.019-26%-0.014-43%
Current Ratio--0.0010.001-3%0.002-58%0.001-46%0.002-67%0.009-92%
Debt To Asset Ratio--1538.503796.393+93%35.945+4180%283.693+442%173.342+788%103.577+1385%
Debt To Equity Ratio----0%-0%-0%-0%-0%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value---27064222.737-25816577.184-5%-12651467.479-53%-15679137.495-42%3012074.603-999%113248727.776-124%
Eps--0.000-0.001+23%0.000-34%-0.001+143%-0.001+142%-0.002+210%
Free Cash Flow Per Share--0.0000.000-101%0.000-100%0.000+10476%0.000+47573%0.000+183537%
Free Cash Flow To Equity Per Share--0.0000.000+353%0.000+1867%0.000+3058%0.000+204%0.000-100%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--0.006----------
Intrinsic Value_10Y_min---0.007----------
Intrinsic Value_1Y_max--0.000----------
Intrinsic Value_1Y_min---0.001----------
Intrinsic Value_3Y_max--0.000----------
Intrinsic Value_3Y_min---0.003----------
Intrinsic Value_5Y_max--0.001----------
Intrinsic Value_5Y_min---0.005----------
Market Cap109792.000-100%219584.263741096.066-70%11593757.521-98%9655779.672-98%25369381.403-99%130820882.701-100%
Net Profit Margin----108.5630%-202.7680%-528.2820%-60.6870%32.363-100%
Operating Margin----62.0040%-129.1520%-339.4750%-327.1450%-145.1920%
Operating Ratio---62.254-100%130.696-100%299.875-100%262.786-100%84.002-100%
Pb Ratio-0.004+50%-0.008-0.028+253%-0.505+6165%-0.405+4925%-1.648+20359%-12.244+151938%
Pe Ratio-0.052+50%-0.103-0.270+162%-1.208+1072%-0.803+680%-3.588+3384%-18.882+18232%
Price Per Share0.000-100%0.0000.001-70%0.010-98%0.008-97%0.022-99%0.119-100%
Price To Free Cash Flow Ratio-146.000+50%-292.000-61.974-79%-115.946-60%-66.956-77%-74.965-74%-135.471-54%
Price To Total Gains Ratio-0.237+50%-0.474-1.132+139%-5.488+1058%-4.500+849%-22.676+4684%-112.008+23529%
Quick Ratio---0.000-100%0.000-100%0.000-100%0.001-100%0.004-100%
Return On Assets---30.054-17.919-40%-0.725-98%-6.764-77%-4.322-86%-6.039-80%
Return On Equity----0%-0%-0%-0%-0%
Total Gains Per Share--0.000-0.001+33%-0.002+410%-0.001+66%-0.001+74%-0.001+21%
Usd Book Value---27266073.000-26432061.750-3%-23517252.250-14%-24592708.000-10%-20970888.950-23%-15883252.875-42%
Usd Book Value Change Per Share--0.000-0.001+33%-0.002+410%-0.001+66%-0.001+74%-0.001+21%
Usd Book Value Per Share---0.025-0.024-3%-0.020-18%-0.021-14%-0.019-26%-0.014-43%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value---27064222.737-25816577.184-5%-12651467.479-53%-15679137.495-42%3012074.603-999%113248727.776-124%
Usd Eps--0.000-0.001+23%0.000-34%-0.001+143%-0.001+142%-0.002+210%
Usd Free Cash Flow---188.00025625.500-101%73205.250-100%-27809.750+14692%-94381.500+50103%-347615.375+184802%
Usd Free Cash Flow Per Share--0.0000.000-101%0.000-100%0.000+10476%0.000+47573%0.000+183537%
Usd Free Cash Flow To Equity Per Share--0.0000.000+353%0.000+1867%0.000+3058%0.000+204%0.000-100%
Usd Market Cap109792.000-100%219584.263741096.066-70%11593757.521-98%9655779.672-98%25369381.403-99%130820882.701-100%
Usd Price Per Share0.000-100%0.0000.001-70%0.010-98%0.008-97%0.022-99%0.119-100%
Usd Profit---532971.000-655223.000+23%-253821.000-52%-1108438.667+108%-1274040.800+139%-1642441.875+208%
Usd Revenue---415.250-100%15271.000-100%23613.167-100%22742.800-100%17111.175-100%
Usd Total Gains Per Share--0.000-0.001+33%-0.002+410%-0.001+66%-0.001+74%-0.001+21%
 EOD+2 -6MRQTTM+13 -18YOY+10 -213Y+16 -155Y+16 -1510Y+14 -18

3.3 Fundamental Score

Let's check the fundamental score of Endonovo Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.052
Price to Book Ratio (EOD)Between0-1-0.004
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.000
Current Ratio (MRQ)Greater than10.001
Debt to Asset Ratio (MRQ)Less than11,538.503
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-30.054
Total1/10 (10.0%)

3.4 Technical Score

Let's check the technical score of Endonovo Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.756
Ma 20Greater thanMa 500.000
Ma 50Greater thanMa 1000.000
Ma 100Greater thanMa 2000.000
OpenGreater thanClose0.000
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Endonovo Therapeutics Inc

Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardiovascular diseases, chronic kidney, liver diseases, non-alcoholic steatohepatitis, cardiovascular and peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, stroke, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.

Fundamental data was last updated by Penke on 2025-06-29 05:18:02.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Endonovo earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Endonovo to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 0.0%Β means thatΒ $0.00 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Endonovo Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-10,856.3%+10,856.3%
TTM-10,856.3%YOY-20,276.8%+9,420.4%
TTM-10,856.3%5Y-6,068.7%-4,787.7%
5Y-6,068.7%10Y3,236.3%-9,305.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--91.7%+91.7%
TTM-10,856.3%-139.0%-10,717.3%
YOY-20,276.8%-194.4%-20,082.4%
3Y-52,828.2%-248.5%-52,579.7%
5Y-6,068.7%-343.3%-5,725.4%
10Y3,236.3%-488.9%+3,725.2%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Endonovo is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Endonovo to theΒ Biotechnology industry mean.
  • -3,005.4% Return on Assets means thatΒ Endonovo generatedΒ $-30.05 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Endonovo Therapeutics Inc:

  • The MRQ is -3,005.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -1,791.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-3,005.4%TTM-1,791.9%-1,213.5%
TTM-1,791.9%YOY-72.5%-1,719.4%
TTM-1,791.9%5Y-432.2%-1,359.7%
5Y-432.2%10Y-603.9%+171.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3,005.4%-11.6%-2,993.8%
TTM-1,791.9%-11.7%-1,780.2%
YOY-72.5%-11.4%-61.1%
3Y-676.4%-11.9%-664.5%
5Y-432.2%-12.1%-420.1%
10Y-603.9%-13.8%-590.1%
4.3.1.3. Return on Equity

Shows how efficient Endonovo is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Endonovo to theΒ Biotechnology industry mean.
  • 0.0% Return on Equity means Endonovo generated $0.00Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Endonovo Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--13.5%+13.5%
TTM--15.0%+15.0%
YOY--14.5%+14.5%
3Y--16.9%+16.9%
5Y--17.9%+17.9%
10Y--19.9%+19.9%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Endonovo Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Endonovo is operatingΒ .

  • Measures how much profit Endonovo makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Endonovo to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Endonovo Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-6,200.4%+6,200.4%
TTM-6,200.4%YOY-12,915.2%+6,714.8%
TTM-6,200.4%5Y-32,714.5%+26,514.1%
5Y-32,714.5%10Y-14,519.2%-18,195.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--229.2%+229.2%
TTM-6,200.4%-249.7%-5,950.7%
YOY-12,915.2%-208.4%-12,706.8%
3Y-33,947.5%-221.7%-33,725.8%
5Y-32,714.5%-344.1%-32,370.4%
10Y-14,519.2%-470.4%-14,048.8%
4.3.2.2. Operating Ratio

Measures how efficient Endonovo is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Endonovo Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM62.254-62.254
TTM62.254YOY130.696-68.442
TTM62.2545Y262.786-200.532
5Y262.78610Y84.002+178.785
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.108-2.108
TTM62.2542.680+59.574
YOY130.6963.080+127.616
3Y299.8753.621+296.254
5Y262.7864.734+258.052
10Y84.0026.546+77.456
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Endonovo Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Endonovo is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 0.00Β means the company has $0.00 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Endonovo Therapeutics Inc:

  • The MRQ is 0.001. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.001. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.001TTM0.0010.000
TTM0.001YOY0.002-0.001
TTM0.0015Y0.002-0.001
5Y0.00210Y0.009-0.007
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0013.659-3.658
TTM0.0013.834-3.833
YOY0.0024.141-4.139
3Y0.0014.661-4.660
5Y0.0025.756-5.754
10Y0.0096.151-6.142
4.4.3.2. Quick Ratio

Measures if Endonovo is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Endonovo to theΒ Biotechnology industry mean.
  • A Quick Ratio of 0.00Β means the company can pay off $0.00 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Endonovo Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.0000.000
TTM0.000YOY0.0000.000
TTM0.0005Y0.001-0.001
5Y0.00110Y0.004-0.003
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.799-2.799
TTM0.0003.143-3.143
YOY0.0003.794-3.794
3Y0.0004.307-4.307
5Y0.0015.707-5.706
10Y0.0046.457-6.453
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Endonovo Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of EndonovoΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Endonovo to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1,538.50Β means that Endonovo assets areΒ financed with 153,850.3% credit (debt) and the remaining percentage (100% - 153,850.3%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Endonovo Therapeutics Inc:

  • The MRQ is 1,538.503. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 796.393. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ1,538.503TTM796.393+742.110
TTM796.393YOY35.945+760.448
TTM796.3935Y173.342+623.051
5Y173.34210Y103.577+69.765
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1,538.5030.324+1,538.179
TTM796.3930.347+796.046
YOY35.9450.329+35.616
3Y283.6930.340+283.353
5Y173.3420.349+172.993
10Y103.5770.379+103.198
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Endonovo is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Endonovo to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Endonovo Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.379-0.379
TTM-0.435-0.435
YOY-0.412-0.412
3Y-0.446-0.446
5Y-0.460-0.460
10Y-0.509-0.509
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Endonovo generates.

  • Above 15 is considered overpriced butΒ always compareΒ Endonovo to theΒ Biotechnology industry mean.
  • A PE ratio of -0.10 means the investor is paying $-0.10Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Endonovo Therapeutics Inc:

  • The EOD is -0.052. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.103. Based on the earnings, the company is expensive. -2
  • The TTM is -0.270. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.052MRQ-0.103+0.052
MRQ-0.103TTM-0.270+0.167
TTM-0.270YOY-1.208+0.938
TTM-0.2705Y-3.588+3.319
5Y-3.58810Y-18.882+15.294
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.052-2.282+2.230
MRQ-0.103-2.062+1.959
TTM-0.270-2.541+2.271
YOY-1.208-3.722+2.514
3Y-0.803-3.754+2.951
5Y-3.588-6.100+2.512
10Y-18.882-6.653-12.229
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Endonovo Therapeutics Inc:

  • The EOD is -146.000. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -292.000. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -61.974. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-146.000MRQ-292.000+146.000
MRQ-292.000TTM-61.974-230.026
TTM-61.974YOY-115.946+53.972
TTM-61.9745Y-74.965+12.991
5Y-74.96510Y-135.471+60.506
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-146.000-3.101-142.899
MRQ-292.000-2.689-289.311
TTM-61.974-3.594-58.380
YOY-115.946-4.363-111.583
3Y-66.956-5.065-61.891
5Y-74.965-8.478-66.487
10Y-135.471-9.273-126.198
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Endonovo is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of -0.01 means the investor is paying $-0.01Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Endonovo Therapeutics Inc:

  • The EOD is -0.004. Based on the equity, the company is expensive. -2
  • The MRQ is -0.008. Based on the equity, the company is expensive. -2
  • The TTM is -0.028. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.004MRQ-0.008+0.004
MRQ-0.008TTM-0.028+0.020
TTM-0.028YOY-0.505+0.476
TTM-0.0285Y-1.648+1.619
5Y-1.64810Y-12.244+10.597
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.0041.932-1.936
MRQ-0.0081.848-1.856
TTM-0.0282.119-2.147
YOY-0.5052.469-2.974
3Y-0.4052.526-2.931
5Y-1.6483.667-5.315
10Y-12.2444.351-16.595
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2024-03-312024-06-302024-09-302024-12-312025-03-31
Total Other Income Expense Net -3090-3090-3090-3093167



6.2. Latest Balance Sheet

Balance Sheet of 2025-03-31. All numbers in thousands.

Summary
Total Assets18
Total Liabilities27,284
Total Stockholder Equity-27,266
 As reported
Total Liabilities 27,284
Total Stockholder Equity+ -27,266
Total Assets = 18

Assets

Total Assets18
Total Current Assets18
Long-term Assets0
Total Current Assets
Cash And Cash Equivalents 0
Other Current Assets 18
Total Current Assets  (as reported)18
Total Current Assets  (calculated)18
+/-0
Long-term Assets
Long-term Assets  (as reported)0
Long-term Assets  (calculated)0
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities27,204
Long-term Liabilities80
Total Stockholder Equity-27,266
Total Current Liabilities
Short Long Term Debt 6,870
Accounts payable 3,359
Other Current Liabilities 6,337
Total Current Liabilities  (as reported)27,204
Total Current Liabilities  (calculated)16,565
+/- 10,639
Long-term Liabilities
Long-term Liabilities Other 80
Long-term Liabilities  (as reported)80
Long-term Liabilities  (calculated)80
+/-0
Total Stockholder Equity
Total Stockholder Equity (as reported)-27,266
Total Stockholder Equity (calculated)0
+/- 27,266
Other
Capital Stock110
Common Stock Shares Outstanding 1,097,921
Net Debt 6,870
Net Invested Capital -20,396
Net Working Capital -27,186



6.3. Balance Sheets Structured

All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302010-12-31
> Total Assets 
170
100
990
1,027
988
969
78
106
74
64
74
186
196
99
46
65
54
62
76
274
102
264
319
358
203
160
4,612
4,471
4,284
4,711
4,242
3,766
4,123
3,414
3,275
3,067
2,896
2,732
2,607
2,522
2,274
2,137
2,007
1,815
1,595
1,451
1,281
1,199
1,015
816
640
476
315
151
19
18
18191513154766408161,0151,1991,2811,4511,5951,8152,0072,1372,2742,5222,6072,7322,8963,0673,2753,4144,1233,7664,2424,7114,2844,4714,612160203358319264102274766254654699196186746474106789699881,027990100170
   > Total Current Assets 
160
100
10
53
26
19
1
33
2
1
3
119
152
58
3
26
18
30
44
246
79
245
303
346
195
155
111
123
99
689
382
69
586
39
63
18
10
9
46
124
39
63
95
64
6
24
16
95
73
36
20
18
18
17
18
18
1818171818203673951624664956339124469101863395866938268999123111155195346303245792464430182635815211931233119265310100160
       Cash And Cash Equivalents 
30
100
10
52
11
3
1
33
2
1
3
80
145
51
1
26
18
27
41
109
79
95
56
113
24
64
90
95
68
665
379
58
548
5
19
0
5
3
13
86
9
6
86
60
0
23
0
11
33
0
2
0
1
0
0
0
00010203311023060866986133501955485837966568959064241135695791094127182615114580312331311521010030
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000030000000000000000000000000000000000000
       Net Receivables 
130
0
0
1
1
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7
10
3
3
10
8
11
23
3
1
1
1
7
9
7
1
1
1
1
0
3
0
0
0
0
0
0
0
0
00000000301111797111323118103310700000000000000000000021100130
       Other Current Assets 
0
0
0
0
14
14
0
0
0
0
0
0
7
7
2
2
0
3
3
137
0
150
247
467
342
91
21
21
42
42
0
0
0
0
0
29
7
5
0
61
41
50
0
7
10
0
16
81
40
36
18
18
18
18
18
18
1818181818183640811601070504161057290000042422121913424672471500137330227700000014140000
   > Long-term Assets 
10
0
980
974
962
949
77
74
72
63
70
67
44
41
43
39
35
32
32
28
24
20
0
12
8
5
0
4,348
4,185
4,023
0
3,697
3,537
3,375
3,212
3,049
2,886
2,723
2,561
2,398
2,236
2,074
1,912
1,751
1,589
1,427
1,265
1,104
942
780
620
458
297
135
2
0
021352974586207809421,1041,2651,4271,5891,7511,9122,0742,2362,3982,5612,7232,8863,0493,2123,3753,5373,69704,0234,1854,34805812020242832323539434144677063727477949962974980010
       Property Plant Equipment 
0
0
0
2
2
1
65
62
60
51
58
55
44
41
43
39
35
32
32
28
24
20
16
12
8
5
1
10
9
8
7
6
7
7
6
4
3
2
2
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000022234677678910158121620242832323539434144555851606265122000
       Intangible Assets 
0
0
980
972
960
948
0
0
0
0
0
12
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,500
4,338
4,177
4,015
3,853
3,691
3,530
3,368
3,206
3,044
2,883
2,721
2,559
2,398
2,236
2,074
1,912
1,751
1,589
1,427
1,265
1,104
942
780
619
0
295
163
0
0
0016329506197809421,1041,2651,4271,5891,7511,9122,0742,2362,3982,5592,7212,8833,0443,2063,3683,5303,6913,8534,0154,1774,3384,50000000000000000120000094896097298000
       Long-term Assets Other 
10
0
0
-2
0
-949
0
-77
0
0
0
12
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,697
3,537
3,375
3,212
0
0
0
0
-2
-2
-2
0
-2
-2
-2
0
-2
-2
-2
0
457
0
-28
0
0
00-2804570-2-2-20-2-2-20-2-2-200003,2123,3753,5373,697000000000000000000012000-770-9490-20010
> Total Liabilities 
0
0
1,420
1,746
2,104
2,395
1,959
2,492
3,090
3,527
4,206
4,940
5,151
4,583
4,739
4,907
5,451
5,991
7,665
9,287
7,353
8,783
8,880
13,425
9,357
13,344
13,564
13,094
13,400
18,793
15,634
15,391
20,369
19,980
23,778
14,209
15,078
15,494
16,981
18,495
19,259
20,355
17,782
19,852
20,755
21,057
33,462
25,568
23,217
23,776
24,746
25,277
25,795
26,330
26,822
27,284
27,28426,82226,33025,79525,27724,74623,77623,21725,56833,46221,05720,75519,85217,78220,35519,25918,49516,98115,49415,07814,20923,77819,98020,36915,39115,63418,79313,40013,09413,56413,3449,35713,4258,8808,7837,3539,2877,6655,9915,4514,9074,7394,5835,1514,9404,2063,5273,0902,4921,9592,3952,1041,7461,42000
   > Total Current Liabilities 
0
0
670
996
1,199
1,645
1,753
2,267
2,880
3,329
4,008
4,743
4,961
4,396
4,555
4,726
5,274
5,813
7,483
9,000
6,962
8,289
8,721
13,269
9,202
13,189
13,409
12,273
12,323
17,474
15,479
15,236
20,214
19,825
23,623
14,054
14,923
15,339
16,826
18,340
19,179
20,275
17,702
19,772
20,675
20,977
33,382
25,488
23,137
23,696
24,666
25,197
25,716
26,250
26,742
27,204
27,20426,74226,25025,71625,19724,66623,69623,13725,48833,38220,97720,67519,77217,70220,27519,17918,34016,82615,33914,92314,05423,62319,82520,21415,23615,47917,47412,32312,27313,40913,1899,20213,2698,7218,2896,9629,0007,4835,8135,2744,7264,5554,3964,9614,7434,0083,3292,8802,2671,7531,6451,19999667000
       Short-term Debt 
0
0
180
415
415
570
236
284
436
495
715
993
1,350
1,208
1,388
1,306
353
1,499
1,519
1,436
1,408
1,559
3,824
2,006
2,380
2,727
4,465
5,462
6,133
7,237
0
4,000
4,437
7,133
0
6,180
6,206
6,101
0
6,736
6,659
6,772
0
7,293
7,357
7,240
0
6,900
7,027
7,057
7,073
7,058
7,016
7,016
6,870
0
06,8707,0167,0167,0587,0737,0577,0276,90007,2407,3577,29306,7726,6596,73606,1016,2066,18007,1334,4374,00007,2376,1335,4624,4652,7272,3802,0063,8241,5591,4081,4361,5191,4993531,3061,3881,2081,35099371549543628423657041541518000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,824
8,413
2,387
2,557
4,465
5,192
5,863
6,967
7,594
6,276
6,782
7,133
6,862
6,180
6,206
6,101
6,634
6,736
6,659
6,772
7,181
7,293
7,357
7,240
7,153
6,900
7,027
7,057
7,073
0
7,016
7,016
0
6,870
6,87007,0167,01607,0737,0577,0276,9007,1537,2407,3577,2937,1816,7726,6596,7366,6346,1016,2066,1806,8627,1336,7826,2767,5946,9675,8635,1924,4652,5572,3878,4133,8240000000000000000000000
       Accounts payable 
0
0
0
1
0
1,075
0
1,984
2,445
2,834
3,294
3,750
3,612
3,188
3,167
3,412
3,757
3,809
3,990
4,223
4,380
4,551
4,727
4,686
4,598
3,238
2,714
2,992
3,070
3,180
157
199
281
346
599
577
609
762
701
722
711
753
658
704
785
866
882
879
917
926
1,080
1,097
1,126
1,130
3,427
3,359
3,3593,4271,1301,1261,0971,0809269178798828667857046587537117227017626095775993462811991573,1803,0702,9922,7143,2384,5984,6864,7274,5514,3804,2233,9903,8093,7573,4123,1673,1883,6123,7503,2942,8342,4451,98401,07501000
       Other Current Liabilities 
0
0
490
-415
784
1,075
1,517
-1
2,445
2,834
3,294
3,294
3,612
3,188
3,167
9
1,164
505
5,964
3,341
1,174
2,179
1,934
6,577
2,225
7,224
5,960
3,819
3,120
7,057
4,426
6,485
10,807
12,346
10,600
7,296
8,108
8,476
4,203
10,882
11,808
12,751
3,442
11,775
12,533
12,872
17,362
17,708
15,193
15,713
16,514
17,042
17,574
18,103
16,445
6,337
6,33716,44518,10317,57417,04216,51415,71315,19317,70817,36212,87212,53311,7753,44212,75111,80810,8824,2038,4768,1087,29610,60012,34610,8076,4854,4267,0573,1203,8195,9607,2242,2256,5771,9342,1791,1743,3415,9645051,16493,1673,1883,6123,2943,2942,8342,445-11,5171,075784-41549000
   > Long-term Liabilities 
0
0
750
750
905
750
207
225
209
198
197
197
190
187
184
181
178
178
183
288
391
495
0
156
155
155
0
821
1,077
1,320
0
155
155
155
155
155
155
155
155
155
80
80
80
80
80
80
80
80
80
80
80
80
80
80
80
80
8080808080808080808080808080808015515515515515515515515515501,3201,0778210155155156049539128818317817818118418719019719719820922520775090575075000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
155
155
155
155
155
155
155
155
155
155
155
155
155
155
155
155
155
80
80
80
80
80
80
80
0
0
0
0
0
0
0
0
0
0000000008080808080808015515515515515515515515515515515515515515515515515500000000000000000000000
> Total Stockholder Equity
170
100
-430
-719
-1,116
-1,426
-1,881
-2,386
-3,016
-3,463
-4,132
-4,754
-4,955
-4,484
-4,693
-4,842
-5,398
-5,929
-7,589
-9,013
-7,250
-8,519
-8,562
-13,066
-9,154
-13,184
-9,550
-8,623
-9,116
-14,082
-11,392
-11,625
-16,247
-16,566
-20,504
-11,142
-12,183
-12,762
-14,374
-15,973
-16,984
-18,218
-15,774
-18,037
-19,160
-19,606
-32,180
-24,369
-22,202
-22,960
-24,106
-24,801
-25,480
-26,179
-26,803
-27,266
-27,266-26,803-26,179-25,480-24,801-24,106-22,960-22,202-24,369-32,180-19,606-19,160-18,037-15,774-18,218-16,984-15,973-14,374-12,762-12,183-11,142-20,504-16,566-16,247-11,625-11,392-14,082-9,116-8,623-9,550-13,184-9,154-13,066-8,562-8,519-7,250-9,013-7,589-5,929-5,398-4,842-4,693-4,484-4,955-4,754-4,132-3,463-3,016-2,386-1,881-1,426-1,116-719-430100170
   Common Stock
0
0
0
5
5
5
5
6
7
8
8
9
5
8
8
10
10
10
10
11
12
12
13
23
24
28
32
34
36
38
43
52
73
83
0
1
1
2
2
5
6
7
7
8
15
16
21
27
28
28
33
34
40
40
54
0
05440403433282827211615877652211083735243383634322824231312121110101010885988765555000
   Retained Earnings -71,564-71,031-70,362-69,665-68,943-68,234-66,631-65,864-67,928-75,119-61,986-61,383-58,857-56,443-58,840-57,316-56,019-53,339-51,308-50,239-48,596-52,935-47,270-45,864-38,027-35,620-37,002-31,054-29,803-29,184-30,953-24,281-26,139-18,374-17,634-15,416-13,962-11,372-8,532-7,331-6,773-6,293-6,070-6,165-5,962-5,333-4,659-4,207-3,567-2,441-1,851-1,458-873-440-560-490
   Capital Surplus 00000000000000000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
660
660
10
149
337
420
554
1,175
1,184
1,188
1,193
1,199
1,205
1,579
1,592
1,957
1,962
2,635
3,819
4,988
8,208
9,162
-2
13,116
15,173
17,874
-2
21,300
22,058
23,040
-2
26,511
29,707
30,704
-2
37,539
38,227
38,631
-2
40,219
40,328
40,616
-2
40,813
42,209
42,366
-2
43,532
43,636
43,646
44,160
44,143
44,144
44,143
44,174
0
044,17444,14344,14444,14344,16043,64643,63643,532-242,36642,20940,813-240,61640,32840,219-238,63138,22737,539-230,70429,70726,511-223,04022,05821,300-217,87415,17313,116-29,1628,2084,9883,8192,6351,9621,9571,5921,5791,2051,1991,1931,1881,1841,17555442033714910660660



6.4. Balance Sheets

All numbers in thousands.




6.5. Cash Flows

All numbers in thousands.




6.6. Income Statements

All numbers in thousands.


6.7. Latest Income Statement

Income Statement (annual), 2024-12-31. All numbers in thousands.

Gross Profit (+$)
totalRevenue10
Cost of Revenue-625
Gross Profit-615-615
 
Operating Income (+$)
Gross Profit-615
Operating Expense-945
Operating Income-1,560-1,560
 
Operating Expense (+$)
Research Development0
Selling General Administrative0
Selling And Marketing Expenses0
Operating Expense9450
 
Net Interest Income (+$)
Interest Income0
Interest Expense-1,237
Other Finance Cost-1,237
Net Interest Income0
 
Pretax Income (+$)
Operating Income-1,560
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-2,797-323
EBIT - interestExpense = -2,797
-2,797
-1,560
Interest Expense1,237
Earnings Before Interest and Taxes (EBIT)-1,560-1,560
Earnings Before Interest and Taxes (EBITDA)-941
 
After tax Income (+$)
Income Before Tax-2,797
Tax Provision-0
Net Income From Continuing Ops0-2,797
Net Income-2,797
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses1,570
Total Other Income/Expenses Net-1,2370
 

Technical Analysis of Endonovo
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Endonovo. The general trend of Endonovo is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Endonovo's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Endonovo Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Endonovo Therapeutics Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 0.0003 < 0.0003 < 0.0003.

The bearish price targets are: 0.0001 > 0.0001 > 0.0001.

Know someone who trades $ENDV? Share this with them.πŸ‘‡

Endonovo Therapeutics Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Endonovo Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Endonovo Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Endonovo Therapeutics Inc. The current macd is 0.00001.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Endonovo price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Endonovo. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Endonovo price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Endonovo Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartEndonovo Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Endonovo Therapeutics Inc. The current adx is 30.86.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Endonovo shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Endonovo Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Endonovo Therapeutics Inc. The current sar is 0.0001.

Endonovo Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Endonovo Therapeutics Inc. The current rsi is 42.76. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Endonovo Therapeutics Inc Daily Relative Strength Index (RSI) ChartEndonovo Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Endonovo Therapeutics Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Endonovo price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Endonovo Therapeutics Inc Daily Stochastic Oscillator ChartEndonovo Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Endonovo Therapeutics Inc. The current cci is 7.8125.

Endonovo Therapeutics Inc Daily Commodity Channel Index (CCI) ChartEndonovo Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Endonovo Therapeutics Inc. The current cmo is -24.29775128.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Endonovo Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartEndonovo Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Endonovo Therapeutics Inc. The current willr is -100.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Endonovo Therapeutics Inc Daily Williams %R ChartEndonovo Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Endonovo Therapeutics Inc.

Endonovo Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Endonovo Therapeutics Inc. The current atr is 0.000056.

Endonovo Therapeutics Inc Daily Average True Range (ATR) ChartEndonovo Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Endonovo Therapeutics Inc. The current obv is -44,130,069.

Endonovo Therapeutics Inc Daily On-Balance Volume (OBV) ChartEndonovo Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Endonovo Therapeutics Inc. The current mfi is 96.44.

The long score for the Money Flow Index (MFI) is 2/2.
The longshort score for the Money Flow Index (MFI) is 2/(-2 +2).

  • MFI > 50: +1
  • MFI > 80: +1
Endonovo Therapeutics Inc Daily Money Flow Index (MFI) ChartEndonovo Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Endonovo Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-02-14STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-02-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-02-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-02-27SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-14STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-19WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-03-24SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-03-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-31STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-07MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-04-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-14STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-23CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-04-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-04-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-05-02WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-05-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-07CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-09CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-05-13CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-21MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-05-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-28CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-06-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-06-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-06-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-17SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-24SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-06-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

Endonovo Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Endonovo Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.756
Ma 20Greater thanMa 500.000
Ma 50Greater thanMa 1000.000
Ma 100Greater thanMa 2000.000
OpenGreater thanClose0.000
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Endonovo with someone you think should read this too:
  • Are you bullish or bearish on Endonovo? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Endonovo? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Endonovo Therapeutics Inc

I send you an email if I find something interesting about Endonovo Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Endonovo Therapeutics Inc.

Receive notifications about Endonovo Therapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.